EUVIMEDEUVIMED entdecken
Crossref

Different Diseases, Different Escapes: Trastuzumab Deruxtecan Resistance in HER2-Amplified versus HER2-Low Breast Cancer

Tess A O'Meara iD, Paolo Tarantino iD

Cancer Discovery · 06.02.2026 · 16 (2) · 195-197

DOI: 10.1158/2159-8290.cd-25-2102 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Discovery, online erschienen am 06.02.2026. Verfasst von Tess A O'Meara und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Hauptthemen laut MEDLINE: Trastuzumab, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this issue of Cancer Discovery, Chen and colleagues demonstrate that, in preclinical models, HER2 expression level directly affects trastuzumab deruxtecan internalization and cytotoxicity, with clinical data revealing divergent target dynamics depending on whether HER2 functions as an oncogenic driver or a dispensable antigen. Together with prior preclinical and clinical evidence, these findings support a context-dependent model in which target downregulation predominates in HER2-low disease, whereas payload resistance or rare binding-site mutations may dominate resistance in HER2-addicted tumors, with important implications for antibody–drug conjugate selection and sequencing. See related article by Chen et al., p. 235

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TrastuzumabBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesDrug Resistance, NeoplasmImmunoconjugatesHumansFemaleAntibodies, Monoclonal, HumanizedAnimalsAntineoplastic Agents, ImmunologicalCamptothecin

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine KinasesImmunoconjugatesERBB2 protein, humantrastuzumab deruxtecanAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCamptothecin

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.
  • Harvard Medical School, Boston, Massachusetts.

ORCID-Profile: Tess A O'Meara, Paolo Tarantino

Zitieren

APA

O'Meara, T. A., & Tarantino, P. (2026). Different Diseases, Different Escapes: Trastuzumab Deruxtecan Resistance in HER2-Amplified versus HER2-Low Breast Cancer. Cancer Discovery, 16(2), 195-197. https://doi.org/10.1158/2159-8290.cd-25-2102

Vancouver

O'Meara TA, Tarantino P. Different Diseases, Different Escapes: Trastuzumab Deruxtecan Resistance in HER2-Amplified versus HER2-Low Breast Cancer. Cancer Discovery. 2026;16(2):195-197. doi:10.1158/2159-8290.cd-25-2102

BibTeX
@article{OMeara2026,
  author = {O'Meara, Tess A and Tarantino, Paolo},
  title = {Different Diseases, Different Escapes: Trastuzumab Deruxtecan Resistance in HER2-Amplified versus HER2-Low Breast Cancer},
  journal = {Cancer Discovery},
  year = {2026},
  volume = {16},
  number = {2},
  pages = {195--197},
  doi = {10.1158/2159-8290.cd-25-2102}
}
Kostenlos starten →